U.S. Markets open in 3 hrs 49 mins

Eliem Therapeutics, Inc. (ELYM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
16.40-2.37 (-12.63%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.77
Open17.99
Bid0.00 x 1000
Ask0.00 x 900
Day's Range16.40 - 17.99
52 Week Range13.65 - 29.69
Volume107,796
Avg. Volume334,403
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Eliem Therapeutics Reports Second Quarter Financial Results

    On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023 SEATTLE and CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address u

  • Benzinga

    Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August

    Following the market opening Monday, the Dow traded down 0.40% to 35,372.03 while the NASDAQ fell 1.27% to 14,634.24. The S&P also fell, dropping 0.57% to 4,442.47. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 36,680,110 cases with around 621,630 deaths. India confirmed a total of at least 32,225,510 cases and 431,640 deaths, while Brazil reported over 20,364,090 COVID-19 cases with 569,050 deaths. In total, there were at least 207,273,290 ca

  • GlobeNewswire

    Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

    SEATTLE and CAMBRIDGE, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, today announced the closing of its initial public offering of 7,360,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 960,000 a